Hypoxia increases normal prostate epithelial cell resistance to receptor-mediated apoptosis via AKT activation

International Journal of Cancer

Volumn 124, Issue 8, 2009, Pages 1871-1878

  Walsh, Sinead ^a   Gill, Catherine ^a   O'Neill, Amanda ^a   Fitzpatrick, John M ^a,b   Watson, R William G ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

Author keywords

AKT; Apoptosis; Hypoxia; Inhibitor of apoptosis; Prostate

Indexed keywords

CASPASE 8; CYTOCHROME C; DEATH RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BAX; PROTEIN KINASE B; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; BIRC3 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN;

APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL SURVIVAL; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HYPOXIA; MITOCHONDRIAL MEMBRANE; PRIORITY JOURNAL; PROSTATE EPITHELIUM; PROTEIN PHOSPHORYLATION; ANOXIA; BIOLOGICAL MODEL; EPITHELIUM CELL; MALE; METABOLISM; MITOCHONDRION; PATHOLOGY; PHOSPHORYLATION; PROSTATE TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANOXIA; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CASPASE 8; EPITHELIAL CELLS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MALE; MITOCHONDRIA; MODELS, BIOLOGICAL; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING;

EID: 62449171070     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24145     Document Type: Article

References (30)

1. Tanaka T, Kato H, Kojima I, Ohse T, Son D, Tawakami T, Yatagawa T, Inagi R, Fujita T, Nangaku M. Hypoxia and expression of Hypoxia-Inducible Factor in the aging kidney. J Gerontol Ser A Biol Sci Med Sci 2006;61:795-805.
2. Aalami O, Fang TD, Song HM, Nacamuli RP. Physiological features of aging persons. Arch Surg 2003;138:1068-76.
3. Katschinski DM. Is there a molecular connection between hypoxia and aging? Exp Gerontol 2006;41:482-4.
4. Sanchez-Chapado M, Olmedilla G, Cabeza M, Donat E, Ruiz A. Prevalence of prostate cancer and prostatic intraepithelial neoplasia in Caucasian Mediterranean males: an autopsy study. Prostate 2003;54:238-47.
5. Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, Ratcliffe PJ, Harris AL. The expression and distribution of the hypoxia-inducible factors HIF1alpha and HIF2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 2000;157:411-21.
6. Ghafer MA, Puchner PJ, Anastasiadis AG, Cabelin MA, Buttyan R. Does the prostatic vascular system contribute to the development of benign prostatic hyperplasia? Curr Urol Rep 2002;3:292-6.
7. Berger AP, Bartsch G, Deibl M, Alber H, Pachinger O, Fritsche G, Rantner B, Fraedrich G, Pallwein L, Aigner F, Horninger W, Frauscher F. Atherosclerosis as a risk factor for benign prostatic hyperplasia. Br J Urol Int 2006;98:1038-42.
8. Berger AP, Deibl M, Halpern EJ, Lechleitner M, Bektic J, Horninger W, Fritsche G, Steiner H, Pelzer A, Bartsch G, Frauscher F. Vascular damage induced by type 2 diabetes mellitus as a risk factor for benign prostatic hyperplasia. Diabetologica 2005;48:784-9.
9. Sampson N, Untergasser G, Plas E, Berger P. The ageing male reproductive tract. J Pathol 2007;211:206-18.
10. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007;26:225-39.
11. McCarty MF. Targeting multiple signaling pathways as a strategy for managing prostate cancer: multifocal signal modulation therapy. Integr Cancer Ther 2004;3:349-80.
12. Du Z, Fujiyama C, Chen Y, Masaka Z. Expression of hypoxia-inducible factor 1 alpha in human normal, benign, and malignant prostate tissue. Chin Med J 2003;116:1936-9.
13. Zhong H, Semenza GL, Simons JW, De Marzo AM. Up-regulation of hypoxia-inducible factor 1 alpha is an early event in prostate carcinogenesis. Cancer Detect Prev 2004;28:88-93.
14. Coffey R, Morrissey C, Taylor C, Fitzpatrick JM, Watson RWG. Resistance to caspase dependent hypoxia-induced apoptosis is not HIF-1alpha mediated in androgen independent prostate cancer cells. Cancer 2005;103:1363-74.
15. McCrohan AM, Morrissey C, O'Keane C, Mulligan N, Watson C, Smith J, Fitzpatrick JM, Watson RW. Effects of the Dual 5 alpha-reductase inhibitor Dutasteride on apoptosis in primary cultures of prostate cancer epithelial cells. Cancer 2006;106:2743-52.
16. Gill C, Walsh S, Morrissey C, Fitzpatrick JM, Watson RW. Resveratrol sensitises androgen independent prostate cancer cells to death-receptor mediated apoptosis through multiple mechanisms. Prostate 2007;67:1641-53.
17. Xu Q, Reed JC. Bax inhibitor-1, a mammalian apoptosis suppressor identified by functional screening in yeast. Mol Cell 1998;1:337-46.
18. Roy N, Deveraux QL, Takahashi R, Salvesen GS, Reed JC. The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J 1997;16:6914-25.
19. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS Jr. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998; 281:1680-3.
20. Partheniou F, Kelsey SM, Srinivasula SM, Newland AC, Alnemri ES, Jia L. c-IAP1 blocks TNFalpha-mediated cytotoxicity upstream of caspase-dependent and -independent mitochondrial events in human leukemic cells. Biochem Biophys Res Commun 2001;287:181-9.
21. Parker C, Milosevic M, Toi A. Polarographic electrode study of tumor oxygenation in clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2004;58:750-7.
22. Cretney E, Takeda K, Yagita H, Glaccum M, Peschon JJ, Smyth MJ. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol 2002; 168:1356-61.
23. Nagaraj NS, Vigneswaran N, Zacharias W. Hypoxia inhibits TRAIL-induced tumor cell apoptosis: involvement of lysosomal cathepsins. Apoptosis 2007;12:125-30.
24. Erler JT, Cawthorne CJ, Williams KJ, Koritzinsky M, Wouters BG, Wilson C, Miller C, Demonacos C, Stratford IJ, Dive C. Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance. Mol Cell Biol 2004;24:2875-89.
25. Kim H, Kim YN, Kim H, Kim CW. Oxidative stress attenuates Fas-mediated apoptosis in Jurkat T cell line through Bfl-1 induction. Oncogene 2005;24:1252-61.
26. Dong Z, Venkatachalam MA, Wang J, Patel Y, Saikumar P, Semenza GL, Force T, Nishiyama J. Up-regulation of apoptosis inhibitory protein IAP-2 by hypoxia. Hif-1-independent mechanisms. J Biol Chem 2001;276:18702-9.
27. Chen X, Thakkar H, Tyan F, Gim S, Robinson H, Lee C, Pandey SK, Nwokorie C, Onwudiwe N, Srivastava RK. Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer. Oncogene 2001;20:6073-83.
28. Jiang BH, Jiang G, Zheng JZ, Lu Z, Hunter T, Vogt PK. Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ 2001;12:363-9.
29. Mabjeesh NJ, Willard MT, Frederickson CE, Zhong H, Simons JW. Androgens stiulate hypoxia-indcible factor 1 activation via autocrine loop of tyrosine kinase receptor/phophatidylinositol 30-kinase/protein kinase B in prostate cancer cells. Clin Cancer Res 2003;9:2416-25.
30. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, Simons JW, Semenza GL. Modulation of hypoxia-inducible factor 1 alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 2000;60:1541-5.